Needham analyst Ami Fadia has maintained their neutral stance on NBIX stock, giving a Hold rating yesterday.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Ami Fadia has given his Hold rating due to a combination of factors surrounding Neurocrine’s recent performance and outlook. The company’s 2025 sales guidance for Ingrezza, a key product, was set at $2.5-2.6 billion, which falls short of market expectations of $2.66 billion. This conservative outlook, with little growth anticipated from the fourth quarter of 2024, may raise concerns among investors about future performance.
Despite these concerns, Fadia acknowledges the potential for growth driven by Neurocrine’s expanded sales force and the growing VMAR2i class, suggesting that there could be upside to the current guidance. Additionally, the early positive trends in prescriptions for Crenessity indicate broad usage and provide some encouragement. As a result, Fadia maintains a cautious stance with the Hold rating, awaiting further clarity on the company’s future prospects.
According to TipRanks, Fadia is a 4-star analyst with an average return of 4.2% and a 46.75% success rate. Fadia covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Merus, and Immuneering.
In another report released yesterday, RBC Capital also maintained a Hold rating on the stock with a $148.00 price target.